Combined STAT3 and BCR-ABL1 Inhibition Induces Synthetic Lethality in Therapy-Resistant Chronic Myeloid Leukemia

Mutations in the BCR-ABL1 kinase domain are an established mechanism of tyrosine kinase inhibitor (TKI) resistance in Philadelphia chromosome-positive leukemia, but fail to explain many cases of clinical TKI failure. In contrast, it is largely unknown why some patients fail TKI therapy despite conti...

Descripción completa

Detalles Bibliográficos
Autores principales: Eiring, Anna M., Page, Brent D. G., Kraft, Ira L., Mason, Clinton C., Vellore, Nadeem A., Resetca, Diana, Zabriskie, Matthew S., Zhang, Tian Y., Khorashad, Jamshid S., Engar, Alexander J., Reynolds, Kimberly R., Anderson, David J., Senina, Anna, Pomicter, Anthony D., Arpin, Carolynn C., Ahmad, Shazia, Heaton, William L., Tantravahi, Srinivas K., Todic, Aleksandra, Moriggl, Richard, Wilson, Derek J., Baron, Riccardo, O'Hare, Thomas, Gunning, Patrick T., Deininger, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334758/
https://www.ncbi.nlm.nih.gov/pubmed/25134459
http://dx.doi.org/10.1038/leu.2014.245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334758/
https://www.ncbi.nlm.nih.gov/pubmed/25134459
http://dx.doi.org/10.1038/leu.2014.245

Ejemplares similares